<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659878</url>
  </required_header>
  <id_info>
    <org_study_id>HBR/052/00436-2/2015</org_study_id>
    <secondary_id>DE RKEB/IKEB:4317-2015</secondary_id>
    <nct_id>NCT02659878</nct_id>
  </id_info>
  <brief_title>Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage</brief_title>
  <official_title>Incidence, Influencing Factors and Outcome of Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Debrecen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Debrecen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pupose:&#xD;
&#xD;
      Takotsubo cardiomyopathy is a rare and not well-known complication of the subarachnoid&#xD;
      hemorrhage.&#xD;
&#xD;
      This form of heart failure, called as &quot;broke heart&quot; or &quot;apical ballooning syndrome&quot;, was&#xD;
      first described by Japanese authors at the beginning of 1990's.&#xD;
&#xD;
      1.5-2.2% of acute coronary syndrome is Takotsubo cardiomyopathy. Its predisposing factors,&#xD;
      hypothetical parthenogenesis, diagnostic criteria and therapeutic methods are already known&#xD;
      from the literature.&#xD;
&#xD;
      The study intends to include all patients over 18 years of age who were admitted to our&#xD;
      clinic within 48 hours after the bleeding regardless of gender, neurological status or age.&#xD;
&#xD;
      Data to be registered within 24 hours after admittance:&#xD;
&#xD;
      Instruments:&#xD;
&#xD;
        -  Intracranial blood flow characteristics:TCCD - using Transcranial Color Doppler;&#xD;
           systolic, diastolic and mean blood flow velocity, Systolic / Diastolic ratio,&#xD;
           pulsatility index&#xD;
&#xD;
        -  ECG abnormalities: Corrected QT Interval (QTc), T wave, ST segment, arrhythmia&#xD;
&#xD;
        -  Echocardiography (Ejection fraction%, exact location and degree of cardiac wall motion&#xD;
           abnormalities) - documented with video recording&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The risk of Takotsubo cardiomyopathy (TS) is increased if SAH is associated with more severe&#xD;
      state, a greater degree of bleeding, intraventricular and/ or intracerebral hemorrhage.&#xD;
&#xD;
      The definitive care of patients is postponed due to the appearance of TS, which could affect&#xD;
      the final outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data to be registered within 24 hours after admittance:&#xD;
&#xD;
        -  Age of the patient&#xD;
&#xD;
        -  Gender&#xD;
&#xD;
        -  Comorbidities&#xD;
&#xD;
        -  Currently taken medications&#xD;
&#xD;
        -  The exact time point of bleeding&#xD;
&#xD;
        -  Additional circumstances of the bleeding&#xD;
&#xD;
        -  Physical stress factors&#xD;
&#xD;
        -  Psychological stress factors&#xD;
&#xD;
        -  Significant blood pressure elevation, and its assumed reason&#xD;
&#xD;
        -  Severity of bleeding:Fisher's Grade; Neurological status; Hunt-Hess scale;GCS (Glasgow&#xD;
           Coma Scale)&#xD;
&#xD;
        -  Intracranial blood flow characteristics:TCCD - using Transcranial Color Doppler;&#xD;
           systolic, diastolic and mean blood flow velocity, Systolic / Diastolic ratio,&#xD;
           pulsatility index&#xD;
&#xD;
        -  Cardiac status:Chest pain, Shortness of breath, Pulmonary edema&#xD;
&#xD;
        -  ECG abnormalities: Corrected QT Interval (QTc), T wave, ST segment, arrhythmia&#xD;
&#xD;
        -  Enzyme level associated with myocardial tissue necrosis: Cardiac troponin I (cTnI),&#xD;
           creatine kinase (CK), CK-MB, Brain natriuretic peptide (BNP), N-terminal prohormone of&#xD;
           brain natriuretic peptide (NT-proBNP)&#xD;
&#xD;
        -  The amount of urine collected in 24 hours and determination of urine metanephrine,&#xD;
           normetanephrine levels&#xD;
&#xD;
        -  Chest X-ray&#xD;
&#xD;
        -  Echocardiography (Ejection fraction%, exact location and degree of cardiac wall motion&#xD;
           abnormalities) - documented with video recording&#xD;
&#xD;
        -  Medication: Nimodipine, simvastatin, keeping Mg levels in the normal range, ulcer&#xD;
           prophylaxis, painkillers&#xD;
&#xD;
        -  Fluid therapy: ensuring normovolaemia&#xD;
&#xD;
      Data to be recorded during hospital stay:&#xD;
&#xD;
        -  Localization of the bleeding (is there an aneurysm present, if yes what is its location,&#xD;
           size)&#xD;
&#xD;
        -  Is ventricular drain necessary?&#xD;
&#xD;
        -  Treatment methods of the aneurysm:Endovascular, aneurysm clipping&#xD;
&#xD;
        -  Time passed between bleeding and treatment (in hours)&#xD;
&#xD;
      The following investigations are repeated daily:&#xD;
&#xD;
        -  12-lead ECG&#xD;
&#xD;
        -  Myocardial necrotic enzymes (checked daily over 1 week even if no ECG abnormalities are&#xD;
           present) : cardiac troponin I (cTnI), creatine kinase (CK), CK-MB, Brain natriuretic&#xD;
           peptide (BNP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP)&#xD;
&#xD;
        -  In case of ECG abnormalities echocardiography should take place on the same day (with&#xD;
           video recording)&#xD;
&#xD;
        -  If there are no ECG abnormalities echocardiography should be controlled once within the&#xD;
           first week (with video recording)&#xD;
&#xD;
        -  Transcranial Color Doppler (TCCD)&#xD;
&#xD;
        -  Glasgow Coma Scale (GCS)&#xD;
&#xD;
        -  Recording the currently used medicines with accurate doses (with special attention to&#xD;
           the positive inotropic agents and drugs with vasoconstrictor properties)&#xD;
&#xD;
        -  In case of mechanical ventilation:Fraction of inspired oxygen (FiO 2), Positive end&#xD;
           expiratory pressure (PEEP), Blood gas analysis (PaO 2, PaCO 2), Peak pressure (PPeak)&#xD;
&#xD;
        -  Noting the presence of pulmonary edema (auscultation, blood gas analysis) If Takotsubo&#xD;
           cardiomyopathy is diagnosed, the 24-hour urine collection test should be repeated&#xD;
           (measure the quantity of collected urine, determine urine metanephrine and&#xD;
           normetanephrine levels)&#xD;
&#xD;
      The following diagnostic steps should be repeated after 1 month:&#xD;
&#xD;
        -  Echocardiography&#xD;
&#xD;
        -  12-lead ECG&#xD;
&#xD;
        -  New York Heart Association scores (NYHA scores)&#xD;
&#xD;
        -  Glasgow outcome scale (GOS) - survival index&#xD;
&#xD;
        -  Bartel Index, Karnofsky score - index of life quality&#xD;
&#xD;
        -  The amount of urine collected in 24 hours and determination of urine metanephrine,&#xD;
           normetanephrine levels&#xD;
&#xD;
      If echocardiography shows cardiac wall motion abnormality, cardiac examination should be&#xD;
      carried out as the following:&#xD;
&#xD;
        -  Cardiac stress test if necessary&#xD;
&#xD;
        -  CT coronary angiogram if necessary&#xD;
&#xD;
        -  Coronary angiography if necessary&#xD;
&#xD;
      The following examinations should be carried out after 6 months:&#xD;
&#xD;
        -  Echocardiography&#xD;
&#xD;
        -  12-lead ECG&#xD;
&#xD;
        -  New York Heart Association scores (NYHA scores)&#xD;
&#xD;
        -  Glasgow outcome scale (GOS) - survival index&#xD;
&#xD;
        -  Bartel Index&#xD;
&#xD;
        -  The amount of urine collected in 24 hours and determination of urine metanephrine,&#xD;
           normetanephrine levels&#xD;
&#xD;
      Comments:&#xD;
&#xD;
      The level of metanephrine and normetanephrine from 24-hour collected urine should be measured&#xD;
      again after 1 and 6 months in case of patients where TS was diagnosed.&#xD;
&#xD;
      The urine of patients who have no diagnosed TS will be solely collected and serve as a&#xD;
      control. Only 15 of these urine samples will be randomly measured to metanephrine /&#xD;
      normetanephrine.&#xD;
&#xD;
      Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the&#xD;
      circumstances of bleeding neurological and cardiological status are recorded, laboratory&#xD;
      tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are&#xD;
      carried out within 24 hours after the patient is being admitted to the ICU.&#xD;
&#xD;
      The medication to prevent vasospasm (Nimodipine, Simvastatin, sustained physiological Mg&#xD;
      level) and ulcers, just like the drugs to relief pain are the same in case of all patients.&#xD;
&#xD;
      The goal of fluid therapy is to maintain normovolaemia. The location of the bleeding is&#xD;
      recorded (is there any aneurysm, its size is measured; if ventricular drainage is necessary,&#xD;
      the method that used to treat aneurysm: endovascular, clipping; time elapsed between bleeding&#xD;
      and therapy) 12-lead ECG, cardiac enzymes, TCCD measurement, neurological state, medications&#xD;
      and its doses, blood gas analysis in case of mechanical ventilation and ventilation&#xD;
      parameters are carried out and recorded on a daily basis.&#xD;
&#xD;
      Cardiac ultrasound and 12-lead ECG examinations are carried out, NYHA scores, clinical&#xD;
      outcome (GOS), quality of life (Bartel Index) and Karnofsky scores are recorded after 1&#xD;
      month.&#xD;
&#xD;
      If echocardiography shows cardiac wall motion abnormality, cardiac examination should be&#xD;
      carried out as following: cardiac stress test, coronary CT angiogram and coronary angiography&#xD;
      if necessary.&#xD;
&#xD;
      Echocardiography, 12-lead ECG examinations are repeated and NYHA scores, clinical outcome&#xD;
      (GOS), quality of life (Bartel Index) and Karnofsky scores are recorded after 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ECG abnormalities:Corrected QT Interval (QTc), T wave, ST segment, arrhythmia</measure>
    <time_frame>Data to be registered within 24 hours after admittance</time_frame>
    <description>12-lead ECD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG abnormalities:Corrected QT Interval (QTc), T wave, ST segment, arrhythmia</measure>
    <time_frame>The following diagnostic steps should be repeated after 1 month</time_frame>
    <description>12-lead ECD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine metanephrine, normetanephrine levels</measure>
    <time_frame>The amount of urine collected in 24 hours</time_frame>
    <description>The amount of urine collected in 24 hours and determination of urine metanephrine, normetanephrine levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine metanephrine, normetanephrine levels</measure>
    <time_frame>The following diagnostic steps should be repeated after 1 month</time_frame>
    <description>The level of metanephrine and normetanephrine from 24-hour collected urine should be measured again after 1 and 6 months in case of patients where TS was diagnosed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Enzyme level associated with myocardial tissue necrosis</measure>
    <time_frame>Data to be registered within 24 hours after admittance</time_frame>
    <description>Cardiac troponin I (cTnI), creatine kinase (CK), CK-MB, Brain natriuretic peptide (BNP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Enzyme level associated with myocardial tissue necrosis</measure>
    <time_frame>The following diagnostic steps should be repeated after 1 month</time_frame>
    <description>Cardiac troponin I (cTnI), creatine kinase (CK), CK-MB, Brain natriuretic peptide (BNP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ejection fraction%, exact location and degree of cardiac wall motion abnormalities</measure>
    <time_frame>Data to be registered within 24 hours after admittance</time_frame>
    <description>Echocardiography documented with video recording</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ejection fraction%, exact location and degree of cardiac wall motion abnormalities</measure>
    <time_frame>The following diagnostic steps should be repeated after 1 month</time_frame>
    <description>Echocardiography documented with video recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association scores (NYHA scores) Glasgow outcome scale (GOS) - survival index Neurological status</measure>
    <time_frame>The following examinations should be carried out after 6 months:</time_frame>
    <description>Clinical outcome (GOS), quality of life (Bartel Index) and Karnofsky scores</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Takotsubo Cardiomyopathy</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bleeding, intraventricular and/ or intracerebral hemorrhage.</intervention_name>
    <description>Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study intends to include all patients over 18 years of age who were admitted to our&#xD;
        clinic within 48 hours after the bleeding regardless of gender, neurological status or age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute subarachnoid hemorrhage&#xD;
&#xD;
          -  Admittance to the neurosurgery intensive care unit within 48 hours after the bleeding&#xD;
             has occurred&#xD;
&#xD;
          -  Over 18 years of age&#xD;
&#xD;
          -  No prior cardiological diseases in medical history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known myocardial diseases (previous myocardial infarction)&#xD;
&#xD;
          -  Preexisting heart failure&#xD;
&#xD;
          -  Previously known structural heart disease (severe, clinically significantvalve&#xD;
             insufficiency, and / or significant stenosis)&#xD;
&#xD;
          -  Preexisting myocarditis&#xD;
&#xD;
          -  Preexisting phaecromocytoma&#xD;
&#xD;
          -  Preexisting hypertrophic cardiomyopathy (Left ventricle &gt; 15 mm)&#xD;
&#xD;
          -  Preexisting coronary artery stenosis that requires dilation (patients should be&#xD;
             excluded if coronary artery stenosis with dilation need is confirmed during the&#xD;
             follow-up period)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Csilla Molnár, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care Debrecen, Hungary, 4032</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judit Gál, MD</last_name>
    <phone>+36-52-255-347</phone>
    <email>anesztezia@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erzsébet Igbonu-Nagy</last_name>
    <phone>+36-20-3991551</phone>
    <email>nagyboske@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judit Gál, MD</last_name>
      <phone>+36-52-255-347</phone>
      <email>anesztezia@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Csilla Molnár, MD, PhD</last_name>
      <phone>+36-30-299-8097</phone>
      <email>csmolnar@med.unideb.hu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1936878X13008176</url>
    <description>Echocardiographic Correlates of Acute Heart Failure, Cardiogenic Shock, and In-Hospital Mortality in Tako-Tsubo Cardiomyopathy</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0736467912014552</url>
    <description>Stress Cardiomyopathy: Case Series and the Review of Literature Vinoda Sharma, MRCP, Manivannan Srinivasan, MRCP, Daniel Mark Sheehan, MBCH, Adrian Ionescu, MRCP</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0735109709036146</url>
    <description>Natural History and Expansive Clinical Profile of Stress (Tako-Tsubo) Cardiomyopathy Scott W. Sharkey, MD</description>
  </link>
  <link>
    <url>http://www.internationaljournalofcardiology.com/article/S0167-5273(09)01637-4/abstract</url>
    <description>Takotsubo cardiomyopathy - The current state of knowledge Agata Bielecka-Dabrowa, Dimitri P. Mikhailidis, Simon Hannam, Jacek Rysz, Marta Michalska, Yoshihiro J. Akashi, Maciej Banach</description>
  </link>
  <link>
    <url>http://www.internationaljournalofcardiology.com/article/S0167-5273(14)00903-6/abstract</url>
    <description>Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy☆ Kuljit Singhcorrespondenceemail, Kristin Carson, Zafar Usmani, Gagandeep Sawhney, Ranjit Shah, John Horowitz</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1936878X13008176</url>
    <description>Echocardiographic Correlates of Acute Heart Failure, Cardiogenic Shock, and In-Hospital Mortality in Tako-Tsubo Cardiomyopathy Rodolfo Citro, MD</description>
  </link>
  <link>
    <url>http://www.thecdt.org/article/view/3459/4520</url>
    <description>Usefulness of MRI in takotsubo cardiomyopathy: a review of the literature Andres Alejandro Kohan1</description>
  </link>
  <reference>
    <citation>Castillo Rivera AM, Ruiz-Bailén M, Rucabado Aguilar L. Takotsubo cardiomyopathy--a clinical review. Med Sci Monit. 2011 Jun;17(6):RA135-47. Review.</citation>
    <PMID>21629203</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>January 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Debrecen</investigator_affiliation>
    <investigator_full_name>Tamas Vegh, MD</investigator_full_name>
    <investigator_title>assistant lecturer anesthesiologist and intensive care specialist</investigator_title>
  </responsible_party>
  <keyword>Takotsubo cardiomyopathy;NT-proBNP;urine metanephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Takotsubo Cardiomyopathy</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

